These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15943478)

  • 1. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands.
    Spadoni G; Bedini A; Guidi T; Tarzia G; Lucini V; Pannacci M; Fraschini F
    ChemMedChem; 2006 Oct; 1(10):1099-105. PubMed ID: 16955531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of MT1 and MT2 receptors.
    Farce A; Chugunov AO; Logé C; Sabaouni A; Yous S; Dilly S; Renault N; Vergoten G; Efremov RG; Lesieur D; Chavatte P
    Eur J Med Chem; 2008 Sep; 43(9):1926-44. PubMed ID: 18255198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
    Attia MI; Witt-Enderby PA; Julius J
    Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screening assay for new ligands at human melatonin receptors.
    Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists.
    Zlotos DP; Attia MI; Julius J; Sethi S; Witt-Enderby PA
    J Med Chem; 2009 Feb; 52(3):826-33. PubMed ID: 19193160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists.
    Spadoni G; Bedini A; Diamantini G; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Caronno A; Fraschini F
    ChemMedChem; 2007 Dec; 2(12):1741-9. PubMed ID: 17907131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, NMR conformational analysis and pharmacological evaluation of 7,7a,13,14-tetrahydro-6H-cyclobuta[b]pyrimido[1,2-a:3,4-a']diindole analogues as melatonin receptor ligands.
    Attia MI; Güclü D; Hertlein B; Julius J; Witt-Enderby PA; Zlotos DP
    Org Biomol Chem; 2007 Jul; 5(13):2129-37. PubMed ID: 17581657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
    Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
    Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
    Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
    J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.
    Bedini A; Lucarini S; Spadoni G; Tarzia G; Scaglione F; Dugnani S; Pannacci M; Lucini V; Carmi C; Pala D; Rivara S; Mor M
    J Med Chem; 2011 Dec; 54(24):8362-72. PubMed ID: 22047556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂.
    Devavry S; Legros C; Brasseur C; Cohen W; Guenin SP; Delagrange P; Malpaux B; Ouvry C; Cogé F; Nosjean O; Boutin JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):15-21. PubMed ID: 22202844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
    Larraya C; Guillard J; Renard P; Audinot V; Boutin JA; Delagrange P; Bennejean C; Viaud-Massuard MC
    Eur J Med Chem; 2004 Jun; 39(6):515-26. PubMed ID: 15183910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.